Kura Oncology to Participate in Upcoming Investor Conference

Rhea-AI Summary

Kura Oncology (Nasdaq: KURA) will participate in the Jefferies Global Healthcare Conference on November 19, 2025. The company is scheduled to present at 3:30 p.m. GMT / 10:30 a.m. ET / 7:30 a.m. PT.

A live audio webcast will be available in the Investors section of Kura Oncology's website, with an archived replay posted after the event.

News Market Reaction

-0.09%

5 alerts

-0.09% News Effect

+2.2% Peak Tracked

-14.9% Trough Tracked

-$899K Valuation Impact

$998M Market Cap

0.5x Rel. Volume

On the day this news was published, KURA declined 0.09%, reflecting a mild negative market reaction. Argus tracked a peak move of +2.2% during that session. Argus tracked a trough of -14.9% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $899K from the company's valuation, bringing the market cap to $998M at that time.

Data tracked by StockTitan Argus on the day of publication.

SAN DIEGO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the following investor conference:

Jefferies Global Healthcare Conference
November 19, 2025
3:30 p.m. GMT / 10:30 a.m. ET / 7:30 a.m. PT

A live audio webcast will be available in the Investors section of Kura’s website at https://kuraoncology.com/, with an archived replay available following the event.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura is developing ziftomenib, a menin inhibitor targeting certain genetic drivers of acute myeloid leukemias, and continues to pioneer advancements in menin inhibition for acute leukemias and solid tumors and in farnesyl transferase inhibition to address mechanisms of adaptive and innate resistance in the treatment of solid tumors. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn.

Contacts

Investors and media:
Greg Mann
858-987-4046
gmann@kuraoncology.com

FAQ

When will Kura Oncology (KURA) present at the Jefferies Global Healthcare Conference?

Kura Oncology will present on November 19, 2025 at 3:30 p.m. GMT / 10:30 a.m. ET / 7:30 a.m. PT.

How can investors listen to Kura Oncology's (KURA) presentation on November 19, 2025?

A live audio webcast will be available in the Investors section of Kura Oncology's website, with an archived replay after the event.

Where will the archived replay of Kura Oncology's (KURA) Jefferies presentation be posted?

The archived replay will be posted on Kura Oncology's investor website at https://kuraoncology.com/ following the event.

Will Kura Oncology (KURA) provide slides or materials for the Jefferies Global Healthcare Conference presentation?

The announcement specifies a live audio webcast and an archived replay on the company website; no slides or additional materials were mentioned.

Is the Jefferies Global Healthcare Conference presentation by Kura Oncology (KURA) open to the public?

The live audio webcast is available through Kura Oncology's investor website, which typically allows public access to the stream.